Intensity Therapeutics INTS
NASDAQ INTS
$3.51 +0.23 (+7.01%)
As of: Oct 21, 2026 · 10:37 AM EDT

Intensity Therapeutics (INTS) Debt Ratio (2022)

Updated

Intensity Therapeutics' Debt Ratio came in at 2.47 for Q4 2022.

Analysis

Intensity Therapeutics (INTS) Debt Ratio (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Eli Lilly 1,132.10 Bn 1,100.69 Bn 19.71 Bn 0.39
2 Johnson & Johnson 615.67 Bn 534.20 Bn 17.26 Bn 0.24
3 AbbVie 504.61 Bn 477.72 Bn 12.70 Bn 0.52
4 Merck 368.03 Bn 322.41 Bn 12.21 Bn 0.42
5 Novartis Ag 298.24 Bn 262.23 Bn 11.24 Bn 0.08
6 Astrazeneca 261.77 Bn 235.46 Bn 12.86 Bn 0.28
7 Amgen 236.17 Bn 191.57 Bn 7.24 Bn 0.60
8 Gilead Sciences 190.62 Bn 164.81 Bn 6.22 Bn 0.53
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 0.31
10 Intensity Therapeutics 9.50 Mn -29.26 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 2.47
API Access

Intensity Therapeutics Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=INTS&period=max&api_key=YOUR_API_KEY